Because microglia change across tissue contexts and functional states, a single signal cannot represent the full range of biology. No one marker captures every microglial state. A stronger interpretation therefore considers what the selected target measures, then relates that signal to the tissue context rather than treating it as a complete microglial profile.
These targets provide marker-specific molecular information, but their presence should not be treated as interchangeable evidence of an identical microglial condition. IBA1, TMEM119, and P2RY12 may be examined as proteins or transcripts, depending on the assay. Comparing their signals with the chosen method and tissue context helps prevent overinterpreting any single readout.
Assay specificity and tissue context are central sources of variation. Immunohistochemistry, flow cytometry, transcriptomic profiling, and positron emission tomography do not present the same type of measurement: they can emphasize cellular, molecular, transcript, or imaging-level information. Consequently, similar-looking results may not answer the same biological question, and conclusions should be tied to the assay used.
They can support comparisons between homeostatic and disease-associated microglia, but they do not automatically establish a complete phenotype. Interpretation depends on the marker set, assay specificity, and tissue context. In neuroscience studies, the most defensible use is to treat biomarker patterns as evidence for comparison across conditions, rather than assigning a state from one isolated measurement.
Method selection should follow the information required. Immunohistochemistry can support tissue-based analysis, flow cytometry can support cellular measurements, transcriptomic profiling can examine transcripts, and positron emission tomography can measure targets such as TSPO in imaging studies. These options address different experimental readouts, so the platform should match whether the study emphasizes tissue, cells, transcripts, or imaging.
TSPO serves as an imaging target that can be measured with positron emission tomography. This makes it useful when a study requires an imaging-based readout rather than only tissue, cellular, or transcript-level analysis. Its signal still requires contextual interpretation, because biomarker meaning depends on assay specificity and the surrounding nervous-system tissue.
They help researchers compare microglial patterns across settings such as neurodegeneration, inflammation, injury, and brain development. The same broad goal can be approached through tissue staining, cellular analysis, transcriptomic profiling, or imaging, depending on the study design. These applications connect measurable microglial features with disease-related, developmental, or injury-associated questions.